Action Regulation Behavioral

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Jul 2, 2024

Keywords

ClinConnect Summary

This clinical trial, called Action Regulation Behavioral, is focused on understanding how Parkinson's disease affects the way patients control their actions and behavior. Parkinson's disease is a condition that impacts movement and can also lead to difficulties in thinking and making decisions. The researchers want to see if a type of treatment that works with a brain chemical called dopamine can help improve these action control issues in people with Parkinson's. By studying how patients respond to this treatment, the researchers hope to find ways to enhance daily functioning and overall quality of life for those living with the disease.

To be part of this study, participants need to have been diagnosed with Parkinson's disease by a specialist and be currently taking a specific medication that helps manage their symptoms. They should also be able to complete tasks for up to 3.5 hours and not have significant problems with vision or hearing. The study is open to individuals aged 65 to 74 and 29 to 219, and it is currently looking for both people with Parkinson's and healthy participants. Those who join the study can expect to participate in various tasks designed to assess their action control abilities. This research aims to deepen our understanding of Parkinson’s disease and potentially lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• For Parkinson's Disease Patients:
• Inclusion Criteria:
• • Diagnosis of Parkinson's Disease by a movement disorder neurologist
• • Levodopa responsive with clearly defined "on" periods, with at least 30% improvement in UPDRS III scores on vs off
• • Willingness and ability to complete the behavioral experiments for up 3.5 hours
• • No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators
• Exclusion Criteria:
• • Patients with history of secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's Disease
• • Patients with a disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocol including cognitive decline, diagnosed forms of dementia, significant memory impairment (MoCA\<23), or hearing loss that prevents adequate communication with researcher
• For Healthy subjects:
• Inclusion Criteria:
• • No history any diagnosed neurological disease(s), including movement disorders or cognitive decline
• • No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators